Report overview
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
This report aims to provide a comprehensive presentation of the global market for Broluzumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Broluzumab Biosimilars. This report contains market size and forecasts of Broluzumab Biosimilars in global, including the following market information:
Global Broluzumab Biosimilars Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Broluzumab Biosimilars Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Broluzumab Biosimilars companies in 2022 (%)
The global Broluzumab Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Beovu Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Broluzumab Biosimilars include Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Broluzumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Broluzumab Biosimilars Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Broluzumab Biosimilars Market Segment Percentages, by Type, 2022 (%)
Beovu
Vsiqq
Others
Global Broluzumab Biosimilars Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Broluzumab Biosimilars Market Segment Percentages, by Application, 2022 (%)
ARMD
Kaposi Sarcoma
Glioblastoma
Global Broluzumab Biosimilars Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Broluzumab Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Broluzumab Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Broluzumab Biosimilars revenues share in global market, 2022 (%)
Key companies Broluzumab Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Broluzumab Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Outline of Major Chapters:
Chapter 1: Introduces the definition of Broluzumab Biosimilars, market overview.
Chapter 2: Global Broluzumab Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Broluzumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Broluzumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Broluzumab Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
